The Oral mucositis market size in 2026 is a painful inflammatory condition affecting the mucous membranes inside the mouth. It is a common complication of cancer treatments, particularly among patients receiving intensive chemotherapy or radiation therapy for head and neck cancers. The condition can cause oral ulcers, pain, difficulty swallowing, and challenges with food intake. These complications may affect patients' quality of life and interrupt cancer treatment schedules.
According to fortune business insights, the oral mucositis market size was valued at USD 1.63 billion in 2025. The market is projected to grow from USD 1.75 billion in 2026 to USD 3.12 billion by 2034, exhibiting a CAGR of 7.46% during the forecast period. The market is witnessing steady expansion due to the increasing number of cancer patients undergoing chemotherapy and radiotherapy and growing awareness of supportive oncology care.
The market includes pharmaceutical and biotechnology companies developing therapies and supportive care products for the management of oral mucositis. Amgen Inc. and Pfizer Inc. are identified among the leading companies by market share. Competition is influenced by clinical research, product development, treatment effectiveness, and the expansion of supportive oncology care portfolios.
Market Drivers